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Tapausseloste Williamsin syndroomaa sairastavasta lapsesta, jolla diagnosoitiin ensin 
Burkittin lymfooma ja myöhemmin Ewingin sarkooma  
 
Williamsin syndrooma on verrattain harvinainen kehityshäiriö (prevalenssi 1/10 000), jonka saa 
aikaan kromosomaalinen mikrodeleetio toisessa kromosomin 7 kopiossa alueella 11q23. Noin 28 
geenin kattava deleetio saa aikaan tyypillisen fenotyypin, johon kuuluu sydämen epämuodostuma 
(tavallisesti supravalvulaarinen aorttastenoosi), tyypilliset kasvonpiirteet sekä älyllinen 
kehitysvammaisuus, joka on vaihtelevan tasoista.  Oireyhtymälle tyypillisiin neurokognitiivisiin 
erityispiirteisiin kuuluvat kielen kehityksen viivästyminen, puutteet näönvaraisessa tulkinnassa sekä 
ylenpalttinen empaattisuus.  
 
Williamsin syndrooman ei ole osoitettu lisäävän riskiä sairastua syöpään. Kuitenkin useat julkaisut 
ovat osoittaneet, että kromosomin 7 mutaatiot ovat tavallisia useissa erityyppisissä kasvaimissa. 
Erityisesti hematologisissa maligniteeteissa ja pediatrisissa sarkoomissa kromosomitranslokaatiot 
ovat yleisiä, mutta mekanismi, joka saa aikaan translokaation syntymisen, ymmärretään vain 
osittain.  
 
Kuvaamme ainutlaatuisen potilaan, jolla on varhaislapsuudessa diagnosoitu kehityshäiriö, 
Williamsin syndrooma. Potilas sairasti myöhemmin sekä Burkittin lymfooman että Ewingin 
sarkooman. Molempien syöpien osalta potilas on nyt remissiossa. Edeltävästi kirjallisuudessa on 
raportoitu ainoastaan 14 tapausta, joissa Williamsin syndroomaa sairastavalla on diagnosoitu jokin 
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Abstract 
 
Williams syndrome (WS) is a relatively rare multisystem neurodevelopmental disorder caused by a 
hemizygous deletion of contiguous genes on chromosome 7q11.23. Although WS does not 
predispose carriers to cancers, alterations of chromosome 7 are common in several human 
neoplasms. We report here a patient with WS and two different cancers, Burkitt lymphoma and 
Ewing sarcoma. Array-CGH analysis of the patient blood revealed a constitutive 1.4 million base 
pair deletion at 7q11.23, compatible with WS diagnosis. 




Williams syndrome (WS, also known as Williams-Beuren syndrome) is a genetic disorder caused 
by a deletion of 26-28 genes at chromosome 7q11.23. The prevalence of the disorder is 
approximately 1 in 10 000 [1]. The patients with WS have various clinical characteristics including 
facial dysmorphia (prominent ear lobes, flat nasal bridge, epicanthal folds, wide mouth with full 
cheeks, etc.), cardiovascular abnormalities (particularly supravalvular aortic stenosis), short stature 
and mental retardation of a varying degree. The distinctive neurocognitive profile of WS consists of 
a delay in early language skills, deficits in visual-motor integration, overfriendliness and a strong 
sense of empathy[1]. Here we report a WS patient who encountered two different malignant tumors, 




The patient was diagnosed with WS at the age of two years based on typical clinical characteristics 
including facial dysmorphia, a heart murmur due to supravalvular stenosis, growth deficiency and 
delay in neurological development. Diagnosis was further confirmed by fluorescence in situ 
hybridization (FISH) of blood nucleated cells showing deletion at chromosome 7q11.23.  
At the age of nine years the patient suffered from acute abdominal pain and was suspected 
of appendicitis. Ultrasound of the abdomen showed thickening of the wall of ascending colon near 
the area of the caecum, and abdominal CT revealed a mass of 3.7 x 3.6 x 9.2 cm. A laparotomy was 
performed, and histological and genetic analyses of the tumor were consistent with the diagnosis of 
Burkitt lymphoma (cytogenetics: t(8;14)(q24;q32)). No dissemination was observed in further 
examinations (CT of head and thorax, ultrasound of para-aortic and parailiac lymph nodes, bone 
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marrow sampling). The patient received chemotherapy according to the A-group of LMB-89 
protocol (dexamethasone, prednisone, cyclophosphamide, vincristine, doxorubicin, and intrathecal 
methotrexate) and did not face any major complications during the treatment.  
Six years later, the patient was again sent to further examinations due to weight loss and 
continuous pain in the right thigh and lower back. MRI revealed a tumor mass in the lumbar 
vertebra L3, partially filling the spinal canal. The histological and cytogenetic analyses confirmed 
Ewing sarcoma (cytogenetics: t(11;22)(q24;q12)). Chemotherapy was carried out according to the 
ISG/SSG III protocol (vincristine, doxorubicin, cyclophosphamide, actinomycin D, ifosfamide, and 
etoposide) and local irradiation was administered up to 54 Gy. Apart from nutritional problems, the 
patient withstood treatments well. The MRI of the trunk and the spine and the flow cytometry of the 
bone marrow aspirate showed no signs of the tumor at the end of the treatment.  
The unusual combination of two separate cancers prompted us to perform further genetic 
analyses. An array-CGH analysis of the blood nucleated cells was performed, showing a 1.4Mb 
deletion at chromosome 7q11.23 (Fig. 1), compatible with the Williams syndrome diagnosis. The 
deletion consists of 27 genes including CLIP2, GTF2IRD1 and GTF2I, and can be categorized as 
“classical” according to Delgado et al [2].  No other constitutive genetic changes were identified 
and both parents had normal array-CGH results.  
 
  
   
Fig. 1. The array-CGH results are shown in a diagram of chromosome 7. The deletion 7q11.23 is 
indicated with red hybridization signals, and next to the diagram is an enlargement of the deleted 
region of size 1.4Mb. 
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Discussion 
 
WS is caused by a deletion of varying length on chromosome 7, leading to an abolition of around 
26–28 coding genes with poorly known functions. The deletion in Williams–Beuren syndrome 
chromosomal region (WBSCR), which occurs sporadically, arises as a consequence of 
chromosomal misalignment during meiosis due to highly similar low-copy-repeat sequences 
flanking the region [1]. Exactly how this deletion leads to the characteristic phenotype of WS is 
unknown. 
 It has been suggested that 7q11 locus contains potential tumor suppressor genes whose 
deletion might predispose carriers to hematopoietic malignancies as well as some solid tumors. The 
presence of only one copy of each gene in WBSCR region can reduce gene expression by half and 
although this occurs with most of the genes in this locus, there are tissue-specific exceptions, such 
as GTF2IRD1 (general transcription factor II-I repeat domain- containing protein 1) [1]. 
Interestingly, several non-deleted genes that flank the region display decreased expression, possibly 
due to the position effect [1]. 
Many human malignancies have genetic alterations at chromo- some 7 with the most 
common finding in the lymphoid, myeloid, and non-epithelial cancers being monosomy 7. Other 
alterations include trisomy of chromosome 7 and various deletions of the long arm. Deletions at 
7q11 has been reported in acute lymphoblastic leukemia, chronic myeloid leukemia and breast 
carcinoma [3]. Should the microdeletion at 7q11.23 in WS abolish crucial tumor suppressor 
gene(s), one would expect an increased incidence of malignancies. In a study by Hasle et al. [4], 
malignancy was not observed in any of the 16 patients with WS in their cohort, thus not suggesting 
an increased risk of malignancy among WS patients. 
Chromosomal translocations are common particularly in hematological malignancies and 
pediatric sarcomas. Thousands of chromosome translocations have been identified but their etiology 
is poorly understood. Spatial organization of the chromatin and certain features of DNA sequence, 
aberrations in DNA-repair pathways and fragile sites all contribute to their genesis [5]. Among 
malignancies in WS patients (Table I), only cases with Burkitt lymphoma have presented with 
chromosomal translocations. It is intriguing that our patient had two separate malignancies with a 
tumor-specific chromosomal translocation in both. As genetic data on tumors accumulates, it is 
interesting to see if chromosomal translocations are more common in tumors among WS patients. 
Secondary malignancies after Burkitt lymphoma are rare. Only a few reports have been 
published on Ewing sarcoma as a secondary malignancy and, among these, Burkitt lymphoma was 
the primary cancer in only one case [20]. As a chemotherapy, our patient received doxorubicin and 
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cyclophosphamide, and one possibility is that the primary treatment contributed to the occurrence 
of the Ewing sarcoma. 
In summary, we report a unique patient with a constitutional chromosome alteration (WS) 
and two separate malignant tumors, both carrying aberrant fusion events. Array-CGH did not reveal 
any additional genetic lesions in our patient. However, our analysis does not rule out the possibility 
of minor insertions, deletions or mutations not identifiable at the level of array-CGH analysis.  
 
 




























Tumor Age group Reference 
Burkitt leukemia  child 6	  
Bilateral Burkitt lymphoma (ovaries)  child 7	  
Burkitt lymphoma  child 8	  
Non-Hodgkin lymphoma  child 9	  
Non-Hodgkin lymphoma  child 10	  
Non-Hodgkin lymphoma  adult 11	  
Pilomyxoid astrocytoma  child 12	  
Oligodendroglioma  adult 13	  
Oesophageal adenocarcinoma  adult 14	  
Fibrous hamartoma  child 15	  
Lymphoblastic leukemia  child 16	  
Pancreatic adenocarcinoma  adult 17	  
Mucinous cystadenoma of ovary  adult 18	  
Astrocytoma  child 19	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